In previous studies, the combination of pravastatin and zoledronate, known as the ZOPRA treatment, was shown to accelerate the RIANS and to decrease radiosensitivity in a number of genetic diseases, including HD, TSC, NF1, and XPD [26,27,28,29]. This evidence concerns the gene ERCC2 and Huntington disease.